Feasibility of quantification based on novel evaluation with stool DNA and fecal immunochemical test for colorectal cancer detection

Table 2 The clinical characteristics of 49 patients with CRC

Group	N	CEA	KRAS(+)	BMP3(+)	NDRG4(+)	FOB(+)	Complex value
Sex
Female	25	14.07 ± 8.03	48%	64%	80%	72%	1014 ± 70.4
Male	24	5.49 ± 2.11	45.83%	41.67%	83.33%	75%	1000 ± 76.19
P value		0.351	0.999	0.156	0.999	0.999	0.992
Age
≥ 60y	24	12.9 ± 7.14	50%12	54.17%	83.33%	80%	1047 ± 68.52
< 60y	25	6.63 ± 4.69	44%	52%	80%	64%	960 ± 75.57
P value		0.001	0.999	0.999	0.999	0.345	0.675
The clinical classification
Stage
Stage I–II	22	2.94 ± 0.95	45.45%	59.09%	86.36%	86.36%	974 ± 68.91
Stage III–IV	27	16.15 ± 8.06	59.09%	48.15%	95.45%	62.96%	1001 ± 83.41
P value		0.003	0.547	0.568	0.488	0.104	0.803
Pathology
Poor	12	11.97 ± 8.04	41.67%	58.33%	83.33%	66.67%	1054 ± 79.58
Moderate	25	17.18 ± 11.79	44%	44%	80%	88%	977.4 ± 69.91
Well	12	2.95 ± 3.82	58.33%	66.67%	83.33%	50%	1111 ± 107.8
P value		0.741^*, 0.10^&, 0.40^#	0.999^*, 0.684^&, 0.495^#	0.495^*, 0.999^&, 0.295^#	0.999^*, 0.999^&, 0.999^#,	0.183^*, 0.68^&, 0.04^#	0.508^*, 0.676^&, 0.294^#

^*The comparison of the poorly affected patients versus the moderately affected patients
^&The comparison of the poorly affected patients versus the well affected patients
^#The comparison of the moderately affected patients versus the well affected patient

ISSN: 1471-230X